# Evaluation of ICP-B208 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct07617493/  
OnCo record `nct07617493` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ICP-B208 in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.

## Summary

Evaluation of ICP-B208 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07617493 by Beijing InnoCare Pharma Tech Co., Ltd., with 539 participants planned, started 2026-07-03 and due to reach its primary completion in 2030-12. Interventions recorded: ICP-B208.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07617493
- Phase: 1/2
- Setting: An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Efficacy of ICP-B208 in Participants of Advanced Solid Tumor Trials
- Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
- Enrolled: 539

## Sources

- ClinicalTrials.gov NCT07617493: https://clinicaltrials.gov/study/NCT07617493

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nct07617493.json